Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity

Abstract

A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least of the polypeptide fragments is antigenic.

1 - 68 . (canceled) 
     
     
         69 . A composition comprising two or more overlapping fragments of a preproinsulin sequence, an adjuvant, and a pharmaceutically acceptable carrier, wherein the two or more overlapping fragments comprise a preproinsulin epitope. 
     
     
         70 . The composition of  claim 69 , wherein the preproinsulin sequence has an amino acid sequence set forth as SEQ ID NO: 1. 
     
     
         71 . The composition of  claim 69 , wherein the two or more overlapping fragments comprise two or more preproinsulin epitopes. 
     
     
         72 . The composition of  claim 69 , wherein each of the two or more overlapping fragments comprises a preproinsulin epitope. 
     
     
         73 . The composition of  claim 69 , wherein at least one of the two or more overlapping fragments comprise a peptide sequence that is not present in either insulin or C-peptides. 
     
     
         74 . The composition of  claim 69 , wherein none of the two or more overlapping fragments exhibit insulin-like metabolic activity in a human subject. 
     
     
         75 . The composition of  claim 69 , wherein the preproinsulin epitope is not solvent accessible in native folded preproinsulin. 
     
     
         76 . The composition of  claim 69 , wherein the preproinsulin epitope comprises one or more of insulin A-chain 1-15, B-chain 9-23, B-chain 11-27, C-peptide 3-27, C-peptide 13-32, or C-peptide 13-29. 
     
     
         77 . The composition of  claim 69 , wherein each of the two or more overlapping fragments comprises a uniform length and a uniform length of overlap. 
     
     
         78 . The composition of  claim 69 , wherein each of the two or more overlapping fragments is 8 to 30 amino acids in length. 
     
     
         79 . The composition of  claim 78 , wherein each of the two or more overlapping fragments is 20 amino acids in length. 
     
     
         80 . The composition of  claim 69 , wherein each of the two or more overlapping fragments overlaps another of the two or more overlapping fragments by 3 to 20 amino acids. 
     
     
         81 . The composition of  claim 80 , wherein each of the two or more overlapping fragments overlaps another of the two or more overlapping fragments by 10 amino acids. 
     
     
         82 . The composition of  claim 69 , wherein the two or more overlapping fragments span the entire length of the preproinsulin sequence. 
     
     
         83 . The composition of  claim 82 , wherein the two or more overlapping fragments comprise 3 to 100 overlapping fragments. 
     
     
         84 . The composition of  claim 83 , wherein each of the two or more overlapping fragments are 20 amino acids in length and overlaps at least one of the other two or more overlapping fragments by 10 amino acids. 
     
     
         85 . The composition of  claim 69 , further comprising an adjuvant that comprises an oil and an emulsifier. 
     
     
         86 . The composition of  claim 85 , wherein the adjuvant comprises an incomplete Freund's adjuvant (IFA). 
     
     
         87 . The composition of  claim 85 , wherein the adjuvant comprises an alum adjuvant. 
     
     
         88 . A method of treating type 1 diabetes mellitus autoimmunity in a subject in need thereof, the method comprising administering the composition of  claim 69  to the subject.